Stockscreener 앱 받기
1.755
6.07%
0.105
전일 마감가:
$1.65
열려 있는:
$1.66
하루 거래량:
154.36K
Relative Volume:
0.24
시가총액:
$218.19M
수익:
-
순이익/손실:
$-35.47M
주가수익비율:
-3.2779
EPS:
-0.5354
순현금흐름:
$-124.27M
1주 성능:
-18.60%
1개월 성능:
-6.41%
6개월 성능:
-52.70%
1년 성능:
-5.91%
1일 변동 폭
$1.65
$1.80
1주일 범위
$1.50
$2.18
52주 변동 폭
$1.18
$4.44
Prokidney Corp Stock (PROK) Company Profile
명칭
Prokidney Corp
전화
336-999-7028
주소
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
PROK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| PROK | 1.755 | 218.19M | 0 | -35.47M | -124.27M | -0.5354 |
| VRTX | 449.69 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.75 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.89 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-21 | 개시 | Jefferies | Buy |
| 2022-11-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-10-18 | 개시 | UBS | Buy |
| 2022-10-14 | 개시 | Citigroup | Buy |
| 2022-09-23 | 개시 | BofA Securities | Buy |
| 2022-09-02 | 개시 | Evercore ISI | Outperform |
모두보기
Prokidney Corp 주식(PROK)의 최신 뉴스
ProKidney no longer coming to Greensboro, Chamber of Commerce confirms - MSN
ProKidney puts is Greensboro factory site up for sale - Winston-Salem Journal
ProKidney: Manufacturing expansion moving to W-S instead of Greensboro - The Business Journals
ProKidney lists Greensboro property for sale, leaving future in city uncertain - WFMYNews2.com
ProKidney lists building where it planned $458M investment for sale - The Business Journals
We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely - Simply Wall St
ProKidney’s Progress in FDA Approval and Financial Health - TipRanks
Prokidney Corp. Reports Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting - Marketscreener.com
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting - The Manila Times
ProKidney Reports Third Quarter 2024 Financial Results - GlobeNewswire
ProKidney Surges on FDA Backing for Phase 3 Study, Reports $406.8M Cash Position | PROK Stock News - StockTitan
Triad's public companies have gained millions in value since election - The Business Journals
Morgan Stanley's Strategic Reduction in ProKidney Corp Holdings - GuruFocus.com
ProKidney: Major Catalyst Is Too Far Away (NASDAQ:PROK) - Seeking Alpha
ProKidney to Participate in the Guggenheim Inaugural - GlobeNewswire
ProKidney (PROK) to Present at Guggenheim and Jefferies Healthcare Conferences | PROK Stock News - StockTitan
ProKidney amends Phase III protocol in light of Phase II results - MSN
Head to Head Review: ProKidney (NASDAQ:PROK) vs. TScan Therapeutics (NASDAQ:TCRX) - Defense World
ProKidney CEO Bruce Culleton named to Triad Power 50 Five to Watch list - The Business Journals
Suvretta Capital Management's Strategic Acquisition in ProKidney Corp - Yahoo Finance
Reviewing ProKidney (NASDAQ:PROK) and Innate Pharma (NASDAQ:IPHA) - Defense World
We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate - Yahoo Finance
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024 - The Manila Times
ProKidney Announces Five Abstracts Selected for - GlobeNewswire
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024 - Yahoo Finance
Stocks of ProKidney Corp (PROK) are poised to climb above their peers - SETE News
Gaining Ground: ProKidney Corp (PROK) Closes Lower at 1.70, Down -0.58 - The Dwinnex
PROK underperforms with a -1.16 decrease in share price - US Post News
ProKidney Corp (PROK) Becoming More Attractive for Investors - Knox Daily
PROK’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
ProKidney to Participate in the UBS Virtual Organ Restoration Day - GlobeNewswire
ProKidney Corp [PROK] Records 50-Day SMA of $2.2292 - Knox Daily
A History of Outperforming Analyst Forecasts and Beating the Odds: ProKidney Corp (PROK) - SETE News
ProKidney Corp (PROK) deserves deeper analysis - US Post News
Recent Insider Activity Suggests Potential Gains for ProKidney Corp (PROK) - Knox Daily
JPMorgan Chase & Co. Initiates Coverage on ProKidney (NASDAQ:PROK) - MarketBeat
An In-Depth Look at ProKidney Corp Inc. (PROK) Price Performance During Market Crashes - The InvestChronicle
ProKidney Corp (PROK)’s Day in Review: Closing at 1.86, Down by -8.82 - The Dwinnex
JPMorgan starts ProKidney stock coverage with Neutral rating - Investing.com
How does ProKidney Corp (PROK) change from a tortoise to a hare? - SETE News
Insider Selling: Weber Darin J., ProKidney Corp [PROK] Chief Regulatory Officer divested 16,412 shares - Knox Daily
Insiders Re-Evaluate Their US$54.7m Stock Purchase As ProKidney Falls To US$659m - Simply Wall St
ProKidney Corp (PROK) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Is it possible to buy ProKidney Corp(PROK) shares at a good price now? - US Post News
Examining the Potential Price Growth of ProKidney Corp (PROK) - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing ProKidney Corp (PROK)’s Performance - The Dwinnex
ProKidney revises Phase 3 program for lead asset - MSN
Reviewing LadRx (OTCMKTS:CYTR) and ProKidney (NASDAQ:PROK) - Defense World
ProKidney (NASDAQ:PROK) Sees Unusually-High Trading Volume - Defense World
ProKidney executive sells $41,030 in company stock By Investing.com - Investing.com Australia
ProKidney Corp. (NASDAQ:PROK) Insider Darin J. Weber Sells 16,412 Shares - MarketBeat
Prokidney Corp (PROK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):